Wahiba Oualikene-Gonin

Hepatitis E and blood donation safety in selected European countries: a shift to screening?

Dragoslav Domanović, Richard S. Tedder, Johannes Blümel et al. · Eurosurveillance · 2017 · 172 citations · Full text

Immunohematology, Organ Donation, Preventive Medicine +23

Regulatory assessment of nano-enabled health products in public health interest. Position of the scientific advisory board of the French National Agency for the Safety of Medicines and Health Products

Wahiba Oualikene-Gonin, Valérie Sautou, Éric Ezan et al. · Frontiers in Public Health · 2023 · 42 citations · Full text

Nanoparticles, Engineering, Nanomaterials Regulations +22

Artificial intelligence integration in the drug lifecycle and in regulatory science: policy implications, challenges and opportunities

Wahiba Oualikene-Gonin, Marie‐Christine Jaulent, Jean-Pierre Thierry et al. · Frontiers in Pharmacology · 2024 · 31 citations · Full text

Artificial Intelligence, Artificial Intelligence Integration, Engineering +20

Prevention and management of health products shortages by the French national agency (ANSM), 10 years of experience

Laëtitia Belgodère, Joseph Emmerich, Nicolas Albin et al. · Frontiers in Public Health · 2023 · 14 citations · Full text

A shared regulatory perspective on deferral from blood donation of men who have sex with men (<scp>MSM</scp>)

Jay S. Epstein, Peter R. Ganz, Rainer Seitz et al. · Vox Sanguinis · 2014 · 10 citations · Full text

Reproductive Health, Gynecology, Regulatory Perspective +18